TC-E 5003 Reduces Hepatic Triglyceride Accumulation in Western Diet-Fed LDL Receptor Knockout and APOE*3-Leiden.CETP Mice
Biomolecules · 02.11.2026 · 16 (11) · 1598
DOI: 10.3390/biom16111598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 02.11.2026. Verfasst von Yiheng Zhang und 7 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Hartstichting.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by accumulation of lipids within hepatocytes. Conflicting evidence exists regarding the role of protein arginine methyltransferase 1 (PRMT1) in MASLD. Here we investigated the outcome of MASLD treatment with the PRMT1 inhibitor TC-E 5003 in mice fed a Western high-fat/high cholesterol diet. Chronic exposure of male low-density lipoprotein receptor knockout mice to 10 mg/kg TC-E 5003 reduced hepatic triglyceride levels (−37%; p < 0.05) and gene expression levels of the lipogenic factors SREBP-1 (−44%; p < 0.05) and FASN (−42%; p < 0.05). In addition, TC-E 5003 lowered pro-atherogenic very-low-density and low-density lipoprotein concentrations and reduced aortic macrophage foam cell accumulation. However, chronic treatment with 10 mg/kg TC-E 5003 was also associated with unexpected toxicity and mortality. A follow-up study in female APOE*3-Leiden.CETP mice showed that chronic treatment with 2.5 mg/kg TC-E 5003 was also associated with a significant reduction in hepatic triglyceride stores (−24%; p < 0.05) in the absence of adverse effects. Radiolabeled lipoprotein flux studies uncovered a 2-fold increase (p < 0.05) in brown adipose tissue triglyceride-derived fatty-acid uptake upon TC-E 5003 treatment, although the contribution of specific PRMT1 inhibition to this effect could not be established. In conclusion, TC-E 5003 consistently reduced hepatic triglyceride accumulation in two mouse models of metabolic dysfunction-associated steatotic liver disease. While the precise contribution of PRMT1 inhibition remains to be established, the present findings demonstrate that treatment with TC-E 5003 exerts robust steatosis-lowering effects in vivo and warrant further investigation as a potential therapeutic approach for MASLD.
Förderung
- Nederlandse Hartstichting
Zitieren
APA
Zhang, Y., Sijsenaar, T. J. P., Wel, E. J. V. D., Pronk, A. C. M., Rensen, P. C. N., Kooijman, S., Eck, M. V., & Hoekstra, M. (2026). TC-E 5003 Reduces Hepatic Triglyceride Accumulation in Western Diet-Fed LDL Receptor Knockout and APOE*3-Leiden.CETP Mice. Biomolecules, 16(11), 1598. https://doi.org/10.3390/biom16111598
Vancouver
Zhang Y, Sijsenaar TJP, Wel EJVD, Pronk ACM, Rensen PCN, Kooijman S, et al. TC-E 5003 Reduces Hepatic Triglyceride Accumulation in Western Diet-Fed LDL Receptor Knockout and APOE*3-Leiden.CETP Mice. Biomolecules. 2026;16(11):1598. doi:10.3390/biom16111598
BibTeX
@article{Zhang2026,
author = {Zhang, Yiheng and Sijsenaar, Timothy J. P. and Wel, Ezra J. van der and Pronk, Amanda C. M. and Rensen, Patrick C. N. and Kooijman, Sander and Eck, Miranda Van and Hoekstra, Menno},
title = {TC-E 5003 Reduces Hepatic Triglyceride Accumulation in Western Diet-Fed LDL Receptor Knockout and APOE*3-Leiden.CETP Mice},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1598},
doi = {10.3390/biom16111598}
}
EUVIMED